(Q87946441)
Statements
Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline (English)
Susan Branford
David T Yeung
Wendy T Parker
Leanne Purins
Jodi A Braley
Haley K Altamura
Alexandra L Yeoman
Jasmina Georgievski
Bronte A Jamison
Stuart Phillis
Zoe Donaldson
Mary Leong
Linda Fletcher
John F Seymour
Andrew P Grigg
Timothy P Hughes